Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma
Alexander M.M. Eggermont(University Medical Center Utrecht), Caroline Robert(Institut Gustave Roussy), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Michal Kiciński(European Organisation for Research and Treatment of Cancer), Dirk Schadendorf(National Center for Tumor Diseases), Clemens Krepler(Merck & Co., Inc., Rahway, NJ, USA (United States)), Andrey Meshcheryakov(Russian Cancer Research Center NN Blokhin), Jean‐Jacques Grob(Aix-Marseille Université), Sandrine Marréaud(European Organisation for Research and Treatment of Cancer), Shahneen Sandhu(The University of Melbourne), Paul Lorigan(Manchester Academic Health Science Centre), Georgina V. Long(The University of Sydney), Stéphane Dalle(Hospices Civils de Lyon), Dmitri Grebennik(Merck & Co., Inc., Rahway, NJ, USA (United States)), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Alexander C. J. van Akkooi(The University of Sydney), James Larkin(Trinity College Dublin), Susana Puig(Instituto de Salud Carlos III), Stefan Suciu(St James's University Hospital), Matteo S. Carlino(The University of Sydney), Christian U. Blank(The Netherlands Cancer Institute), Andrew Haydon(The Alfred Hospital), Alfonsus Johannes Maria van den Eertwegh(Radboud University Nijmegen), Rahima Jamal(Centre Hospitalier de l’Université de Montréal), Anna Maria Di Giacomo(University of Siena), Victoria Atkinson(Greenslopes Private Hospital), Marye J. Boers‐Sonderen(Radboud University Nijmegen), Mario Mandalà(University of Perugia), Adnan Khattak(Edith Cowan University), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum)
Cited by 152
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k